<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Pharmacology of echinocandins and other glucan synthesis inhibitors
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Pharmacology of echinocandins and other glucan synthesis inhibitors
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Pharmacology of echinocandins and other glucan synthesis inhibitors
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Russell E Lewis, PharmD, FCCP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Carol A Kauffman, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Keri K Hall, MD, MS
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 20, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1239292403">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The development of echinocandins, the first class of antifungals to target the fungal cell wall, was a milestone achievement in antifungal chemotherapy. Echinocandins were discovered as fermentation metabolites with antifungal activity during screening programs for new antibiotics [
         <a href="#rid1">
          1
         </a>
         ]. The candidate molecules were subsequently modified to improve solubility, antifungal spectrum of activity, and pharmacokinetic characteristics [
         <a href="#rid2">
          2
         </a>
         ]. Four semi-synthetic echinocandin derivatives have been developed for clinical use:
         <a class="drug drug_general" data-topicid="9175" href="/z/d/drug information/9175.html" rel="external">
          caspofungin
         </a>
         ,
         <a class="drug drug_general" data-topicid="10141" href="/z/d/drug information/10141.html" rel="external">
          micafungin
         </a>
         ,
         <a class="drug drug_general" data-topicid="8744" href="/z/d/drug information/8744.html" rel="external">
          anidulafungin
         </a>
         , and
         <a class="drug drug_general" data-topicid="141155" href="/z/d/drug information/141155.html" rel="external">
          rezafungin
         </a>
         . A fifth compound,
         <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">
          ibrexafungerp
         </a>
         , is a triterpenoid antifungal that is structurally distinct from the echinocandins and is a semisynthetic derivative of the naturally occurring hemiacetal triterpene glycoside enfumafungin.
        </p>
        <p>
         All four echinocandins are structurally similar cyclic hexapeptide antibiotics with modified N-linked acyl lipid side chains  (
         <a class="graphic graphic_figure graphicRef70049" href="/z/d/graphic/70049.html" rel="external">
          figure 1
         </a>
         ), which play a role in anchoring the hexapeptide nucleus to the fungal cell membrane where the drug interacts with the target enzyme complex involved in cell wall synthesis [
         <a href="#rid3">
          3
         </a>
         ].
         <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">
          Ibrexafungerp
         </a>
         , which is also an inhibitor of glucan synthesis in fungi, interacts with the same target enzyme complex as the echinocandins but through another target site that appears to not interact with the lipid membrane in the same fashion. The four large lipopeptide echinocandins (
         <a class="drug drug_general" data-topicid="8744" href="/z/d/drug information/8744.html" rel="external">
          anidulafungin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9175" href="/z/d/drug information/9175.html" rel="external">
          caspofungin
         </a>
         ,
         <a class="drug drug_general" data-topicid="10141" href="/z/d/drug information/10141.html" rel="external">
          micafungin
         </a>
         and
         <a class="drug drug_general" data-topicid="141155" href="/z/d/drug information/141155.html" rel="external">
          rezafungin
         </a>
         ) have limited oral bioavailability and must be administered by intravenous infusion. Ibrexafungerp is unique in that it is absorbed in the gastrointestinal tract after oral administration and is currently available as an oral formulation. Experience with this antifungal class suggests that it is among the best tolerated and safest class of antifungals available.
        </p>
        <p>
         The pharmacology of echinocandin antifungals and the triterpenoid glucan synthesis inhibitor,
         <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">
          ibrexafungerp
         </a>
         , will be reviewed here. Indications for the clinical use of these antifungals, susceptibility testing, and the pharmacology of other systemic antifungal agents, such as amphotericin B, the azoles, and
         <a class="drug drug_general" data-topicid="8451" href="/z/d/drug information/8451.html" rel="external">
          flucytosine
         </a>
         , are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/2430.html" rel="external">
          "Management of candidemia and invasive candidiasis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2459.html" rel="external">
          "Treatment and prevention of invasive aspergillosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/465.html" rel="external">
          "Antifungal susceptibility testing"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/476.html" rel="external">
          "Pharmacology of amphotericin B"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/495.html" rel="external">
          "Pharmacology of azoles"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/472.html" rel="external">
          "Pharmacology of flucytosine (5-FC)"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1239292410">
         <span class="h1">
          OVERVIEW OF CLINICAL USES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Echinocandins are widely used for the treatment of invasive candidiasis, especially in critically ill and neutropenic patients [
         <a href="#rid4">
          4
         </a>
         ]. They are also used for empiric antifungal therapy in patients with neutropenic fever. They are sometimes used in combination with a triazole (eg,
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="100324" href="/z/d/drug information/100324.html" rel="external">
          isavuconazole
         </a>
         , or
         <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">
          posaconazole
         </a>
         ) for the initial treatment of invasive aspergillosis or as part of a combination antifungal regimen with voriconazole or a lipid formulation of amphotericin B for salvage therapy of invasive aspergillosis (see
         <a class="medical medical_review" href="/z/d/html/2459.html" rel="external">
          "Treatment and prevention of invasive aspergillosis"
         </a>
         ). Currently,
         <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">
          ibrexafungerp
         </a>
         is approved only for the treatment of vulvovaginal candidiasis (VVC) [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p>
         The major advantage of echinocandins relative to other antifungal agents is their fungicidal activity against
         <em>
          Candida
         </em>
         spp, including fluconazole-resistant
         <em>
          C. glabrata
         </em>
         and
         <em>
          C. krusei
         </em>
         , combined with their relatively low potential for renal or hepatic toxicity or serious drug-drug interactions. Echinocandins are also currently recommended as the drugs of choice for
         <em>
          C. auris
         </em>
         , although resistance has been reported [
         <a href="#rid6">
          6
         </a>
         ]. Specific recommendations regarding the use of these agents are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/2430.html" rel="external">
          "Management of candidemia and invasive candidiasis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2459.html" rel="external">
          "Treatment and prevention of invasive aspergillosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1400.html" rel="external">
          "Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)", section on 'Addition of an antifungal agent'
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8744" href="/z/d/drug information/8744.html" rel="external">
          Anidulafungin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9175" href="/z/d/drug information/9175.html" rel="external">
          caspofungin
         </a>
         , and
         <a class="drug drug_general" data-topicid="10141" href="/z/d/drug information/10141.html" rel="external">
          micafungin
         </a>
         have been approved by the US Food and Drug Administration (FDA) for the treatment of esophageal candidiasis and invasive candidiasis in adults, and caspofungin has been approved for these indications in children over three months of age. Caspofungin has also been FDA approved in adults and children over three months of age as an empiric antifungal agent for febrile neutropenia and for salvage therapy of invasive aspergillosis in patients who have failed or are intolerant of other antifungal agents. Micafungin has also been FDA approved as a prophylactic agent for the prevention of
         <em>
          Candida
         </em>
         infections in adults undergoing hematopoietic cell transplantation.
         <a class="drug drug_general" data-topicid="141155" href="/z/d/drug information/141155.html" rel="external">
          Rezafungin
         </a>
         is approved for the treatment of candidemia and invasive candidiasis.
         <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">
          Ibrexafungerp
         </a>
         is approved for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC.
        </p>
        <p>
         Because the four echinocandins share a similar spectrum of activity and mechanism of action, most experts consider these drugs to be interchangeable, particularly for the treatment of invasive candidiasis (see
         <a class="medical medical_review" href="/z/d/html/2430.html" rel="external">
          "Management of candidemia and invasive candidiasis in adults"
         </a>
         ).
         <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">
          Ibrexafungerp
         </a>
         should not be considered interchangeable with current echinocandins until further data are available.
        </p>
        <p>
         The four echinocandins differ in terms of their dosing, pathways of metabolic elimination, and drug interaction profile. Therefore, these unique characteristics should be considered when selecting an echinocandin.
        </p>
        <p class="headingAnchor" id="H1239299741">
         <span class="h1">
          MECHANISM OF ACTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Echinocandins and
         <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">
          ibrexafungerp
         </a>
         are noncompetitive inhibitors of beta-D-glucan synthesis. Beta-D-glucans are branched polysaccharides that serve as essential crosslinking components in the cell wall of many pathogenic fungi. By interfering key catalytic subunits (Fks1p and Fks2p) in the beta-(1,3)-D-glucan synthase enzyme complex, echinocandins deplete cell wall glucan crosslinking, resulting in a markedly weakened cell wall structure  (
         <a class="graphic graphic_figure graphicRef67408" href="/z/d/graphic/67408.html" rel="external">
          figure 2
         </a>
         ) [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         Beta-glucans account for approximately 30 to 60 percent of the cell wall mass in yeasts such as
         <em>
          Candida
         </em>
         species [
         <a href="#rid8">
          8,9
         </a>
         ]. Beta-glucan depletion causes loss of resistance to osmotic forces and cell lysis among
         <em>
          Candida
         </em>
         spp, thereby having a fungicidal effect. In filamentous fungi, such as
         <em>
          Aspergillus fumigatus
         </em>
         , the bulk of beta-glucan synthesis is concentrated at the apical tips and branching points of hyphae [
         <a href="#rid10">
          10-12
         </a>
         ]. Among filamentous fungi, echinocandin-induced beta-glucan depletion causes impeded growth at the tips and branching points of hyphae, resulting in dysmorphic hyphae; this growth inhibition has a fungistatic effect [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p>
         Beta-glucans and the intracellular beta-glucan synthase complex blocked by echinocandins are not present in human cells. For this reason, the echinocandins cause less collateral toxicity than amphotericin B formulations or the triazoles and are implicated in fewer drug-drug interactions. In addition, the mechanism of action of the echinocandins appears to complement the antifungal effects of the other antifungal drug classes, offering the potential for combination therapy. (See
         <a class="medical medical_review" href="/z/d/html/2459.html" rel="external">
          "Treatment and prevention of invasive aspergillosis", section on 'Combination therapy'
         </a>
         .)
        </p>
        <p>
         Echinocandins may also amplify host immune responses by unmasking antigenic beta-glucan epitopes, thereby accelerating host cellular recognition and inflammatory responses [
         <a href="#rid14">
          14-18
         </a>
         ]. However, the evidence supporting such immunomodulatory effects is limited to in vitro studies and murine models.
        </p>
        <p class="headingAnchor" id="H1239292431">
         <span class="h1">
          MICROBIOLOGIC ACTIVITY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Given the widespread distribution of beta-glucans in the fungal cell wall and the high degree of homology of
         <em>
          FKS
         </em>
         genes among diverse fungal genera, echinocandins would be predicted to exhibit activity against a wide spectrum of fungal pathogens. However, the echinocandins and
         <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">
          ibrexafungerp
         </a>
         are primarily effective against
         <em>
          Candida
         </em>
         and
         <em>
          Aspergillus
         </em>
         species, with relatively weak activity against other molds and yeasts, including
         <em>
          Cryptococcus neoformans
         </em>
         [
         <a href="#rid3">
          3
         </a>
         ]. Differences in fungal cell wall construction may influence echinocandin penetration or render some fungal species less susceptible to the effects of beta-glucan synthesis inhibition [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1239292438">
         <span class="h2">
          Candida species
         </span>
         <span class="headingEndMark">
          —
         </span>
         All four of the echinocandins exhibit excellent potency against
         <em>
          Candida
         </em>
         spp [
         <a href="#rid19">
          19
         </a>
         ].
         <em>
          C. albicans
         </em>
         ,
         <em>
          C. glabrata
         </em>
         , and
         <em>
          C. tropicalis
         </em>
         are highly susceptible to all three agents, whereas elevated minimum inhibitory concentrations (MICs) have been seen for
         <em>
          C. parapsilosis
         </em>
         and
         <em>
          C. guilliermondii
         </em>
         (
         <a class="graphic graphic_table graphicRef107624" href="/z/d/graphic/107624.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid19">
          19,20
         </a>
         ]. Acquired resistance to the echinocandins remains sporadic [
         <a href="#rid21">
          21,22
         </a>
         ] and varies by region [
         <a href="#rid23">
          23
         </a>
         ] but has been documented for individual cases of infection with
         <em>
          C. albicans
         </em>
         ,
         <em>
          C. glabrata
         </em>
         ,
         <em>
          C. lusitaniae
         </em>
         ,
         <em>
          C. tropicalis
         </em>
         , and
         <em>
          C. parapsilosis
         </em>
         [
         <a href="#rid22">
          22,24-29
         </a>
         ].
        </p>
        <p>
         Of note, there is increasing concern that some triazole-resistant
         <em>
          C. glabrata
         </em>
         bloodstream isolates are also resistant to the echinocandins. In a surveillance study of the in vitro susceptibility of 1669
         <em>
          C. glabrata
         </em>
         bloodstream isolates collected in the United States between 2006 and 2010, 162 isolates (9.7 percent) were resistant to
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          fluconazole
         </a>
         , of which 98.8 percent were also not susceptible to
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         (MIC &gt;0.5 mcg/mL), and 9.3, 9.3, and 8.0 percent were resistant to
         <a class="drug drug_general" data-topicid="8744" href="/z/d/drug information/8744.html" rel="external">
          anidulafungin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9175" href="/z/d/drug information/9175.html" rel="external">
          caspofungin
         </a>
         , and
         <a class="drug drug_general" data-topicid="10141" href="/z/d/drug information/10141.html" rel="external">
          micafungin
         </a>
         , respectively [
         <a href="#rid20">
          20
         </a>
         ]. Of the 162 isolates that were resistant to fluconazole, 18 (11.1 percent) were resistant to one or more of the echinocandins; all of these isolates contained an
         <em>
          FKS1
         </em>
         or
         <em>
          FKS2
         </em>
         mutation. In comparison, there were no echinocandin-resistant strains detected among 110 fluconazole-resistant
         <em>
          C. glabrata
         </em>
         isolates tested between 2001 and 2004, years in which only one echinocandin, caspofungin, was available, and echinocandins were used sparingly. In a population-based analysis of echinocandin resistance in 1380 bloodstream isolates of
         <em>
          C. glabrata
         </em>
         from four United States cities collected between 2008 and 2013, 3 to 4 percent of strains were resistant to all three echinocandins, and approximately one-third of echinocandin-resistant strains were cross-resistant to fluconazole [
         <a href="#rid30">
          30
         </a>
         ]. Nearly all of the isolates with an
         <em>
          FKS1
         </em>
         or
         <em>
          FKS2
         </em>
         mutation were resistant to at least one echinocandin. Worldwide surveillance data from the SENTRY program (2016 to 2018) have reported echinocandin resistance rates ranging from 2.1 to 3.2 percent [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
         A 10-year study of
         <em>
          C. glabrata
         </em>
         bloodstream infections at a single medical center in the United States showed an increase in echinocandin resistance from 4.9 percent in 2001 to 12.3 percent in 2010 [
         <a href="#rid32">
          32
         </a>
         ]. This resistance was confirmed by the presence of
         <em>
          FKS
         </em>
         mutations; strains categorized as susceptible did not possess acquired mutations. Echinocandin resistance was associated with echinocandin treatment. Among 118 episodes of
         <em>
          C. glabrata
         </em>
         infection in which the infecting strain was categorized as susceptible using the clinical breakpoints, 109 (92.4 percent) had successful outcomes at day 10 of treatment with
         <a class="drug drug_general" data-topicid="10141" href="/z/d/drug information/10141.html" rel="external">
          micafungin
         </a>
         . Conversely, among 13 episodes of
         <em>
          C. glabrata
         </em>
         infection in which the strain was categorized as resistant using the clinical breakpoints and treated with micafungin monotherapy, 5 (38.5 percent) did not respond or responded initially but relapsed or recurred. Among 78 fluconazole-resistant isolates, 11 (14.1 percent) were resistant to one or more echinocandins and 8 (10.3 percent) were resistant to all echinocandins. Another retrospective single-center study reported that
         <em>
          FKS
         </em>
         mutations were identified in 18 percent of 72 patients with
         <em>
          C. glabrata
         </em>
         candidemia and were associated with an eightfold risk of treatment failure [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
         Among patients with underlying hematologic disease, infection with an echinocandin-resistant strain of
         <em>
          C. glabrata, C. parapsilosis, or C. tropicalis
         </em>
         was associated with threefold higher rates of 14- and 30-day mortality [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="141155" href="/z/d/drug information/141155.html" rel="external">
          Rezafungin
         </a>
         achieves higher drug exposures relative to older echinocandins, a factor that may allow the drug to retain activity against some resistant strains [
         <a href="#rid35">
          35
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Similarly,
         <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">
          ibrexafungerp
         </a>
         , which appears to bind at a different site of the FKS1/FKS2 enzyme complex, may retain activity against some echinocandin-resistant strains with FKS1/2 mutations that impact
         <a class="drug drug_general" data-topicid="8744" href="/z/d/drug information/8744.html" rel="external">
          anidulafungin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9175" href="/z/d/drug information/9175.html" rel="external">
          caspofungin
         </a>
         , and
         <a class="drug drug_general" data-topicid="10141" href="/z/d/drug information/10141.html" rel="external">
          micafungin
         </a>
         [
         <a href="#rid36">
          36,37
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Most
         <em>
          Candida auris
         </em>
         isolates are susceptible to the echinocandins, but echinocandin resistance is increasing [
         <a href="#rid6">
          6
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2430.html" rel="external">
          "Management of candidemia and invasive candidiasis in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         These findings emphasize the importance of continuing surveillance for resistance using standardized antifungal susceptibility testing. (See
         <a class="medical medical_review" href="/z/d/html/465.html" rel="external">
          "Antifungal susceptibility testing", section on 'Echinocandins'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2430.html" rel="external">
          "Management of candidemia and invasive candidiasis in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1239292445">
         <span class="h3">
          Candida biofilms
         </span>
         <span class="headingEndMark">
          —
         </span>
         Echinocandins and
         <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">
          ibrexafungerp
         </a>
         appear to retain activity against biofilm-embedded
         <em>
          Candida
         </em>
         species. Under sessile biofilm-like conditions, the MICs for amphotericin B and
         <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">
          fluconazole
         </a>
         may increase by 10- to 1000-fold [
         <a href="#rid38">
          38,39
         </a>
         ]. Biofilm growth in
         <em>
          C. albicans
         </em>
         is associated with increased secretion of carbohydrates, including beta-(1,3)-D-glucan [
         <a href="#rid40">
          40
         </a>
         ], which has been shown to directly inhibit the activity of both fluconazole and amphotericin B [
         <a href="#rid41">
          41-43
         </a>
         ]. In contrast, echinocandin and ibrexafungerp MICs are minimally affected when tested in biofilm versus non-biofilm conditions, and a biofilm-embedded inoculum of
         <em>
          C. albicans
         </em>
         can be reduced by &gt;99 percent at the echinocandin concentrations achieved in vivo [
         <a href="#rid38">
          38,39
         </a>
         ]. These in vitro data suggest that echinocandins may be particularly useful antifungal agents for prosthetic device or catheter-associated infections in which biofilm-embedded organisms can be associated with recurrent candidemia.
        </p>
        <p class="headingAnchor" id="H1239292452">
         <span class="h2">
          Other yeasts
         </span>
         <span class="headingEndMark">
          —
         </span>
         Echinocandins and
         <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">
          ibrexafungerp
         </a>
         lack clinically useful activity against
         <em>
          Cryptococcus neoformans
         </em>
         , and
         <em>
          Cryptococcus gattii
         </em>
         , even though beta-(1,3)-D-glucan synthase from
         <em>
          Cryptococcus
         </em>
         spp is exquisitely sensitive to inhibition by
         <a class="drug drug_general" data-topicid="9175" href="/z/d/drug information/9175.html" rel="external">
          caspofungin
         </a>
         , and beta-(1,3)-D-glucan is present in the fungal cell wall [
         <a href="#rid3">
          3
         </a>
         ]. Breakthrough infections with other rare yeasts intrinsically resistant to echinocandins (non-
         <em>
          Candida
         </em>
         , non-
         <em>
          Cryptococcus
         </em>
         ) have been reported in immunocompromised patients during echinocandin treatment and should be considered in the differential diagnosis of fungemia in any patient with recent echinocandin or ibrexafungerp exposure [
         <a href="#rid44">
          44,45
         </a>
         ]. Compensatory cell wall mechanisms, melanin, and drug degradation pathways may contribute to the inherent resistance of this species to echinocandins.
        </p>
        <p class="headingAnchor" id="H1239292466">
         <span class="h2">
          Dimorphic fungi
         </span>
         <span class="headingEndMark">
          —
         </span>
         Echinocandins and
         <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">
          ibrexafungerp
         </a>
         have only modest activity against the mycelial phase of the dimorphic fungi,
         <em>
          Blastomyces dermatitidis
         </em>
         ,
         <em>
          Histoplasma capsulatum
         </em>
         , and
         <em>
          Coccidioides
         </em>
         spp. Echinocandins are not considered to be effective agents for therapy of dimorphic fungal infections.
        </p>
        <p class="headingAnchor" id="H1239292473">
         <span class="h2">
          Aspergillus
         </span>
         <span class="headingEndMark">
          —
         </span>
         Growth of
         <em>
          Aspergillus
         </em>
         species is inhibited at very low echinocandin and
         <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">
          ibrexafungerp
         </a>
         concentrations in vitro, with the effects predominantly observed at apical and sub-apical branching points where cell wall remodeling and beta-glucan synthase are most active [
         <a href="#rid11">
          11,46
         </a>
         ]. As such, MIC endpoints for
         <em>
          Aspergillus
         </em>
         are determined differently for echinocandins and ibrexafungerp than for other antifungals. The lowest echinocandin concentration resulting in grossly abnormal hyphal forms (small, compact, highly branched hyphae as compared with the normally elongated hyphal forms) are defined at the minimum effective concentration (MEC) [
         <a href="#rid13">
          13
         </a>
         ]. MEC ranges for most
         <em>
          Aspergillus
         </em>
         species fall into what would be considered the susceptible range  (
         <a class="graphic graphic_table graphicRef107624" href="/z/d/graphic/107624.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H1239292480">
         <span class="h2">
          Other molds
         </span>
         <span class="headingEndMark">
          —
         </span>
         Echinocandins and
         <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">
          ibrexafungerp
         </a>
         have only modest or weak activity against non-
         <em>
          Aspergillus
         </em>
         molds. This is sometimes more apparent in vivo than in vitro, suggesting that their effects are partially mediated through unmasking of immunogenic epitopes on the fungal cell wall [
         <a href="#rid47">
          47
         </a>
         ]. Modest echinocandin activity has been reported in vitro for some phaeohyphomycetes, including
         <em>
          Alternaria
         </em>
         spp,
         <em>
          Bipolaris
         </em>
         spp,
         <em>
          Cladophialophora bantiana
         </em>
         ,
         <em>
          Phialophora
         </em>
         spp,
         <em>
          Exophiala
         </em>
         spp,
         <em>
          Fonsecaea pedrosi
         </em>
         ,
         <em>
          Paecilomyces variotti
         </em>
         ,
         <em>
          Acremonium strictum
         </em>
         , and
         <em>
          Scedosporium apiospermum
         </em>
         [
         <a href="#rid48">
          48-51
         </a>
         ], but echinocandins are
         <strong>
          not
         </strong>
         used to treat infections due to these organisms.
        </p>
        <p class="headingAnchor" id="H12264177">
         <span class="h2">
          Pneumocystis jirovecii
         </span>
         <span class="headingEndMark">
          —
         </span>
         In experimental models of
         <em>
          Pneumocystis jirovecii
         </em>
         (formerly
         <em>
          P. carinii
         </em>
         ) pneumonia (PCP), echinocandins are effective agents for prophylaxis but are less effective for established pneumonia [
         <a href="#rid52">
          52,53
         </a>
         ]. The limited treatment efficacy of echinocandins can be explained by the fact that the glucan synthase target for echinocandin activity is expressed only during the cystic but not the trophic life cycle of
         <em>
          P. jirovecii
         </em>
         [
         <a href="#rid53">
          53,54
         </a>
         ]. Therefore, fungal clearance of established infection is relatively weak with echinocandins compared with established therapies such as
         <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">
          trimethoprim-sulfamethoxazole
         </a>
         [
         <a href="#rid48">
          48,55
         </a>
         ]. However, the role for echinocandins in treating or preventing PCP in humans is evolving. Case reports of progression of disease in patients receiving echinocandins have been published. (See
         <a class="medical medical_review" href="/z/d/html/1393.html" rel="external">
          "Treatment and prevention of Pneumocystis pneumonia in patients without HIV"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1239292487">
         <span class="h1">
          RESISTANCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although echinocandins are used extensively as a first-line treatment for invasive candidiasis and less commonly as part of salvage regimens for invasive aspergillosis, acquired echinocandin resistance has been relatively rare to date but is possibly increasing, especially among
         <em>
          C. glabrata
         </em>
         and
         <em>
          C. auris
         </em>
         . (See
         <a class="local">
          'Candida species'
         </a>
         above.)
        </p>
        <p>
         Echinocandin resistance is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/465.html" rel="external">
          "Antifungal susceptibility testing", section on 'Echinocandins'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2430.html" rel="external">
          "Management of candidemia and invasive candidiasis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2459.html" rel="external">
          "Treatment and prevention of invasive aspergillosis", section on 'Combination therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1239292494">
         <span class="h1">
          PHARMACOKINETICS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although the echinocandins share similar spectra of activity, each agent differs in its pathway of metabolism, resulting in distinguishable half-lives, drug interaction profiles, and dosing strategies  (
         <a class="graphic graphic_table graphicRef56212" href="/z/d/graphic/56212.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid3">
          3,56
         </a>
         ]. Due to their large molecular weights, echinocandins are minimally absorbed after oral administration and are available only in intravenous formulations. However, the triterpenoid glucan synthesis inhibitor,
         <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">
          ibrexafungerp
         </a>
         , is available in an oral formulation. All four echinocandins and ibrexafungerp exhibit a high degree of binding to plasma proteins and distribute minimally to cerebrospinal fluid, urine, and the eye. Ibrexafungerp achieves high concentrations in the vaginal mucosa and remains soluble at a lower pH [
         <a href="#rid57">
          57
         </a>
         ]. Echinocandins are not primarily metabolized by cytochrome P450 nor are they substrates or inhibitors of P-glycoprotein pumps, making them less likely targets of drug-drug interactions compared with other systemic antifungals (see
         <a class="local">
          'Dosing'
         </a>
         below and
         <a class="local">
          'Renal insufficiency'
         </a>
         below and
         <a class="local">
          'Hepatic insufficiency'
         </a>
         below and
         <a class="local">
          'Drug interactions'
         </a>
         below). However, ibrexafungerp is a substrate of CYP3A4 and P-glycoprotein. In vitro, ibrexafungerp is also an inhibitor of CYP2C8, CYP3A4, the P-glycoprotein transporter, and the OATP1B3 transporter [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H22267050">
         <span class="h2">
          Caspofungin
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9175" href="/z/d/drug information/9175.html" rel="external">
          Caspofungin
         </a>
         exhibits triphasic nonlinear pharmacokinetics [
         <a href="#rid59">
          59
         </a>
         ]. Following an initial intravenous infusion, tissue distribution accounts for an initial rapid fall in plasma levels, followed by gradual re-release of drug from extravascular tissues coupled with slow hepatic metabolism, yielding a net terminal half-life of 27 to 50 hours [
         <a href="#rid56">
          56,60-62
         </a>
         ]. A loading dose followed by a lower once-daily dose is therefore required to attain an initial therapeutic plasma level and avoid drug accumulation. Caspofungin degrades spontaneously and is also metabolized via hydrolysis and N-acetylation to two inactive metabolites [
         <a href="#rid59">
          59,61
         </a>
         ]. It is non-dialyzable, and less than 2 percent of active drug is excreted via the urinary tract.
        </p>
        <p>
         Dose adjustment is unnecessary for patients with renal insufficiency. However, dose reduction for severe hepatic insufficiency is recommended. (See
         <a class="local">
          'Dosing'
         </a>
         below and
         <a class="local">
          'Caspofungin'
         </a>
         below.)
        </p>
        <p>
         Several drugs have been shown to induce the metabolism of
         <a class="drug drug_general" data-topicid="9175" href="/z/d/drug information/9175.html" rel="external">
          caspofungin
         </a>
         :
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9694" href="/z/d/drug information/9694.html" rel="external">
          nevirapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8731" href="/z/d/drug information/8731.html" rel="external">
          efavirenz
         </a>
         ,
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         , and
         <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">
          phenytoin
         </a>
         . An increased maintenance dose of caspofungin is therefore recommended when any of these agents are given concurrently with caspofungin.
        </p>
        <p class="headingAnchor" id="H22267058">
         <span class="h2">
          Micafungin
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10141" href="/z/d/drug information/10141.html" rel="external">
          Micafungin
         </a>
         demonstrates linear elimination pharmacokinetics, producing a terminal half-life of approximately 15 hours in adults [
         <a href="#rid56">
          56,63
         </a>
         ]. It is metabolized hepatically by arylsulfatase, catechol O-methyltransferase, and hydroxylation. Less than 1 percent of unchanged drug is excreted in the urine. Like
         <a class="drug drug_general" data-topicid="9175" href="/z/d/drug information/9175.html" rel="external">
          caspofungin
         </a>
         , it is non-dialyzable, and dose adjustment for renal insufficiency is unnecessary. Elimination pharmacokinetics in advanced hepatic insufficiency are not well defined. Micafungin is subject to relatively few drug-drug interactions.
        </p>
        <p>
         Modest increases in exposure to
         <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">
          sirolimus
         </a>
         ,
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         , and
         <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">
          nifedipine
         </a>
         have been described in patients receiving
         <a class="drug drug_general" data-topicid="10141" href="/z/d/drug information/10141.html" rel="external">
          micafungin
         </a>
         [
         <a href="#rid64">
          64
         </a>
         ]. (See
         <a class="local">
          'Dosing'
         </a>
         below and
         <a class="local">
          'Micafungin'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H22267066">
         <span class="h2">
          Anidulafungin
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8744" href="/z/d/drug information/8744.html" rel="external">
          Anidulafungin
         </a>
         exhibits linear elimination pharmacokinetics that are predictable and relatively stable across a broad range of patient age, weight, sex, and disease states. Anidulafungin is not metabolized but instead eliminated by slow spontaneous degradation, resulting in a terminal half-life of 40 to 50 hours
         <strong>
         </strong>
         [
         <a href="#rid63">
          63
         </a>
         ]. A loading dose is necessary to achieve rapid therapeutic concentrations. Less than one percent of unchanged drug is excreted in the urine. It is non-dialyzable and dose adjustment for renal or hepatic insufficiency is unnecessary. Few drug-drug interactions are expected. (See
         <a class="local">
          'Dosing'
         </a>
         below and
         <a class="local">
          'Anidulafungin'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H2305725480">
         <span class="h2">
          Rezafungin
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="141155" href="/z/d/drug information/141155.html" rel="external">
          Rezafungin
         </a>
         exhibits linear and dose-proportional increases in the Cmax and AUC at daily doses up to 400 mg, with prolonged (terminal t½ 150 hours) elimination. The pharmacokinetics are modestly affected by sex, active infection, body surface area, and serum albumin, but dosing adjustments based on these conditions is not recommended [
         <a href="#rid58">
          58
         </a>
         ]. Rezafungin undergoes minimal metabolism and is excreted mostly unchanged in the feces [
         <a href="#rid65">
          65
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2985108340">
         <span class="h2">
          Ibrexafungerp
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">
          Ibrexafungerp
         </a>
         reaches maximal plasma concentrations four to six hours after oral administration. The Cmax and AUC increased by 32 and 38 percent respectively in healthy volunteers when administered with a high fat meal compared to fasted conditions. The mean steady state volume of distribution is approximately 600 L with high accumulation in vaginal tissue. Ibrexafungerp is eliminated mainly via CYP3A4 metabolism and biliary excretion with an elimination half-life of 20 hours. A mean of 90 percent of the drug (51 percent unchanged) is recovered in the feces and 1 percent is recovered in the urine.
        </p>
        <p class="headingAnchor" id="H1239298142">
         <span class="h1">
          PHARMACODYNAMICS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The plasma drug concentration profile that optimizes the antifungal efficacy of echinocandins and
         <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">
          ibrexafungerp
         </a>
         has been described in animal models of invasive candidiasis and aspergillosis [
         <a href="#rid66">
          66
         </a>
         ]. Echinocandins appear to exhibit concentration-dependent killing against
         <em>
          Candida
         </em>
         spp based upon in vivo studies showing a fungicidal effect proportional to the maximum (peak) plasma drug concentration and a persistent antifungal effect after plasma drug concentration falls below minimum inhibitory concentration (MIC) [
         <a href="#rid66">
          66
         </a>
         ]. Fungicidal efficacy against
         <em>
          Candida
         </em>
         spp also appears to correlate with the area under time-concentration curve to minimum inhibitory concentration ratio (AUC:MIC) [
         <a href="#rid61">
          61
         </a>
         ]. The optimal pharmacodynamic parameters for killing or inhibiting
         <em>
          Aspergillus
         </em>
         spp, however, are not clearly defined [
         <a href="#rid66">
          66,67
         </a>
         ]. Furthermore, therapeutic drug monitoring with standardized plasma drug concentration ranges or targets for echinocandins has not been established, and revised dosing strategies evaluated in animal models have not identified promising dosing tools for further assessment in humans [
         <a href="#rid61">
          61,66
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1239298150">
         <span class="h1">
          DOSING
         </span>
        </p>
        <p class="headingAnchor" id="H18092677">
         <span class="h2">
          Adult dosing
         </span>
         <span class="headingEndMark">
          —
         </span>
         The dosing of echinocandins and
         <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">
          ibrexafungerp
         </a>
         depends upon the indication. Clinicians should consult the drug information topics or the individual topic reviews for each infection for more detailed information about the use of each drug. Details about specific interactions may be obtained by using the
         <a class="external" href="/drug-interactions">
          drug interactions program
         </a>
         included within UpToDate. (See
         <a class="medical medical_review" href="/z/d/html/2430.html" rel="external">
          "Management of candidemia and invasive candidiasis in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2459.html" rel="external">
          "Treatment and prevention of invasive aspergillosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1239299702">
         <span class="h2">
          Pediatric dosing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pharmacokinetic studies demonstrate an increased rate of clearance for
         <a class="drug drug_general" data-topicid="10141" href="/z/d/drug information/10141.html" rel="external">
          micafungin
         </a>
         and
         <a class="drug drug_general" data-topicid="9175" href="/z/d/drug information/9175.html" rel="external">
          caspofungin
         </a>
         among neonates, infants, and younger children compared with adolescents and adults [
         <a href="#rid68">
          68-75
         </a>
         ]. Accordingly, larger doses of micafungin and caspofungin on the basis of milligrams per kilogram are required for small children and infants compared with adults. No large trials have evaluated dosing in low birthweight neonates, a population at high risk for developing invasive candidiasis. Both caspofungin and micafungin have FDA approval for use in children; dosing instructions for caspofungin are based upon body surface area for children aged three months or older [
         <a href="#rid76">
          76
         </a>
         ]. Micafungin is dosed in children four months or older according to body weight and the indications for use [
         <a href="#rid64">
          64
         </a>
         ]. No data are available for pediatric dosing of
         <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">
          ibrexafungerp
         </a>
         .
        </p>
        <p>
         Clinicians should consult the pediatric drug information topics or the individual topic reviews for each infection for more detailed information about the use of each drug. Details about specific interactions may be obtained by using the
         <a class="external" href="/drug-interactions">
          drug interactions program
         </a>
         included within UpToDate. (See
         <a class="medical medical_review" href="/z/d/html/5029.html" rel="external">
          "Treatment of Candida infection in neonates"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6014.html" rel="external">
          "Candidemia and invasive candidiasis in children: Management", section on 'Antifungal agents'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1239299694">
         <span class="h2">
          Dose adjustments
         </span>
        </p>
        <p class="headingAnchor" id="H308526811">
         <span class="h3">
          Enzyme inhibition
         </span>
         <span class="headingEndMark">
          —
         </span>
         Strong CYP3A4 and P-glycoprotein inhibitors (eg,
         <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">
          ketoconazole
         </a>
         ) increased the
         <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">
          ibrexafungerp
         </a>
         AUC by 5.8-fold and Cmax by 2.5-fold. Moderate CYP3A4 inhibitors (eg,
         <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">
          diltiazem
         </a>
         ) increased the ibrexafungerp AUC by 2.5-fold and the Cmax by 2.2-fold, but no dosing adjustment is recommended. Similarly, proton pump inhibitors (eg,
         <a class="drug drug_general" data-topicid="9474" href="/z/d/drug information/9474.html" rel="external">
          pantoprazole
         </a>
         ) decreased the ibrexafungerp AUC by 25 percent and Cmax by 22 percent; this is likely due to pH effects on gastrointestinal absorption, and no dosage adjustment is recommended. Based on these findings, the ibrexafungerp dose should be reduced to 150 mg 12 hours apart for one day with concomitant use of a strong CYP3A inhibitor, and no dosage adjustment is recommended in patients taking weak or moderate CYP3A inhibitors.
        </p>
        <p class="headingAnchor" id="H1401995">
         <span class="h3">
          Enzyme induction
         </span>
         <span class="headingEndMark">
          —
         </span>
         An increased maintenance dose of
         <a class="drug drug_general" data-topicid="9175" href="/z/d/drug information/9175.html" rel="external">
          caspofungin
         </a>
         of 70 mg daily is suggested for adult patients if treated concomitantly with
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         [
         <a href="#rid76">
          76
         </a>
         ]. For pediatric patients receiving rifampin, a dose of 70 mg/m
         <sup>
          2
         </sup>
         (up to 70 mg) of caspofungin is suggested. A similar adjustment of caspofungin is recommended if the patient is concurrently receiving other drugs that are potent inducers of cytochrome P450 3A4 metabolism (eg,
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         ,
         <a class="drug drug_general" data-topicid="8731" href="/z/d/drug information/8731.html" rel="external">
          efavirenz
         </a>
         ,
         <a class="drug drug_general" data-topicid="9694" href="/z/d/drug information/9694.html" rel="external">
          nevirapine
         </a>
         , or
         <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">
          phenytoin
         </a>
         ). (See
         <a class="local">
          'Drug interactions'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H1239298206">
         <span class="h3">
          Renal insufficiency
         </span>
         <span class="headingEndMark">
          —
         </span>
         Echinocandins and
         <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">
          ibrexafungerp
         </a>
         are not extensively cleared by the kidney and are not dialyzable; therefore, dose adjustment is
         <strong>
          not
         </strong>
         required in patients with renal insufficiency, including patients who are receiving hemodialysis or continuous renal replacement therapy (continuous venovenous hemofiltration or continuous venovenous hemodialysis) [
         <a href="#rid64">
          64,76-78
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1239299710">
         <span class="h3">
          Hepatic insufficiency
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8744" href="/z/d/drug information/8744.html" rel="external">
          Anidulafungin
         </a>
         is inactivated by gradual spontaneous degradation and not metabolized hepatically; therefore, dose adjustment for hepatic insufficiency is not needed [
         <a href="#rid77">
          77
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="10141" href="/z/d/drug information/10141.html" rel="external">
          Micafungin
         </a>
         does not require dose reduction for mild or moderate hepatic insufficiency, and no recommendation is available for use in severe hepatic insufficiency [
         <a href="#rid64">
          64
         </a>
         ].
        </p>
        <p>
         For patients with mild hepatic insufficiency (Child-Pugh class A; score ≤6), the
         <a class="drug drug_general" data-topicid="9175" href="/z/d/drug information/9175.html" rel="external">
          caspofungin
         </a>
         prescribing information recommends no dose reduction [
         <a href="#rid59">
          59
         </a>
         ]. For moderate hepatic insufficiency (Child-Pugh class B; score 7 to 9), the prescribing information recommends no reduction in the loading dose but a reduction in the maintenance dose to 35 mg once daily. No recommendation is available for use in severe hepatic insufficiency (Child-Pugh score &gt;9). A pharmacokinetic study in patients with cirrhosis admitted to a liver unit with acute decompensation and intensive care unit (ICU) patients with acute hepatic insufficiency has suggested that dose reduction of caspofungin in those with moderate (Child-Pugh class B; score 7 to 9) or severe hepatic insufficiency (Child-Pugh class C; score 10 to 15) results in suboptimal drug exposures [
         <a href="#rid79">
          79
         </a>
         ]. Based on these data, we favor full doses of caspofungin for patients with hepatic insufficiency (including acute-onset liver dysfunction and cirrhosis) regardless of the severity of hepatic insufficiency to avoid subtherapeutic exposure. An alternative is to use an echinocandin that does not require dose reduction for patients with moderate to severe liver disease.
        </p>
        <p>
         The pharmacokinetics of
         <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">
          ibrexafungerp
         </a>
         are not altered in patients with Child-Pugh Class A or B hepatic impairment. The impact of severe hepatic impairment (Child-Pugh Class C) is unknown.
        </p>
        <p class="headingAnchor" id="H1647359">
         <span class="h3">
          Obesity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Body weight is an important variable influencing the volume of distribution and clearance of echinocandins; higher total body clearance of
         <a class="drug drug_general" data-topicid="9175" href="/z/d/drug information/9175.html" rel="external">
          caspofungin
         </a>
         has been observed among patients &gt;75 kg receiving intensive care [
         <a href="#rid80">
          80-82
         </a>
         ]. In a pharmacokinetic study among patients with body mass index &lt;25, 25 to 40, and &gt;40 kg/m
         <sup>
          2
         </sup>
         ,
         <a class="drug drug_general" data-topicid="10141" href="/z/d/drug information/10141.html" rel="external">
          micafungin
         </a>
         clearance increased in proportion to weight among patients 65 to 150 kg [
         <a href="#rid82">
          82
         </a>
         ]. Similarly, in a pharmacokinetic/pharmacodynamic analysis of the EMPIRICUS trial (micafungin 100 mg daily versus placebo in ICU patients with sepsis and mechanical ventilation), the likelihood of attaining area under time-concentration curve/minimum inhibitory concentration targets decreased as patient weight increased, especially in patients with sequential organ failure assessment scores &gt;10
         <em>
         </em>
         [
         <a href="#rid83">
          83
         </a>
         ]
         <em>
          .
         </em>
        </p>
        <p>
         For patients &gt;75 kg with sepsis and/or mechanical ventilation, we suggest a daily dose increase of 25 to 50 percent for all echinocandins [
         <a href="#rid82">
          82
         </a>
         ]. No data are currently available for
         <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">
          ibrexafungerp
         </a>
         dosing in obesity.
        </p>
        <p class="headingAnchor" id="H331428470">
         <span class="h3">
          Extracorporeal membrane oxygenation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Lipophilic highly protein-bound drugs may be sequestered in the extracorporeal membrane oxygenation (ECMO) circuit resulting in subtherapeutic plasma concentrations. While all four echinocandins and
         <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">
          ibrexafungerp
         </a>
         are highly protein bound in blood,
         <a class="drug drug_general" data-topicid="9175" href="/z/d/drug information/9175.html" rel="external">
          caspofungin
         </a>
         and
         <a class="drug drug_general" data-topicid="10141" href="/z/d/drug information/10141.html" rel="external">
          micafungin
         </a>
         are more hydrophilic (log P values &lt;1) versus
         <a class="drug drug_general" data-topicid="8744" href="/z/d/drug information/8744.html" rel="external">
          anidulafungin
         </a>
         (log P 2.9). Conflicting evidence from ex vivo binding studies versus case suggest a modest impact of the ECMO circuit in echinocandin pharmacokinetics [
         <a href="#rid84">
          84
         </a>
         ]; however, interpretation of these data may be affected by timing of sampling (early versus late in the course of ECMO when circuit binding may be saturated), the ECMO circuit configuration and materials, and pharmacokinetic changes associated with critical illness itself. Therefore, no standard dosing adjustments for echinocandins are available for patients receiving ECMO.
        </p>
        <p class="headingAnchor" id="H1239298213">
         <span class="h1">
          ADVERSE EFFECTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Echinocandins are well tolerated, and all four members of the class have similar types of adverse effects. Serious adverse effects requiring drug discontinuation occur less frequently with the echinocandins than with other classes of systemic antifungals.
        </p>
        <p class="headingAnchor" id="H1239299718">
         <span class="h2">
          Hepatotoxicity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Modest asymptomatic elevations of aminotransferases (in 7 to 14 percent) and alkaline phosphatase (in 4 to 12 percent) are the most frequently reported laboratory abnormalities in healthy volunteers and patients treated with echinocandins [
         <a href="#rid76">
          76
         </a>
         ]. Liver enzyme abnormalities are generally less common in patients treated with echinocandins compared with those receiving amphotericin B formulations or azoles. Although rare, clinically significant hepatitis, hepatomegaly, hyperbilirubinemia, and hepatic failure have been reported with the echinocandins, although causality has not been conclusively established. Regular monitoring of hepatic aminotransferases during echinocandin therapy is suggested.
        </p>
        <p class="headingAnchor" id="H1239299726">
         <span class="h2">
          Infusion and hypersensitivity reactions
         </span>
         <span class="headingEndMark">
          —
         </span>
         Infusion and nonimmune-related histamine-release symptoms, including rash, pruritus, hypotension, bronchospasm, and angioedema, have been reported rarely with each of the echinocandins [
         <a href="#rid3">
          3
         </a>
         ]. Similar to
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         , these reactions are likely mediated by direct stimulation of the mas-related G-protein protein receptor 2 (MRGPRX2) causing histamine release. Such reactions have been reported with
         <a class="drug drug_general" data-topicid="8744" href="/z/d/drug information/8744.html" rel="external">
          anidulafungin
         </a>
         and
         <a class="drug drug_general" data-topicid="141155" href="/z/d/drug information/141155.html" rel="external">
          rezafungin
         </a>
         when the drug is infused at a rate that exceeds 1.1 mg/minute [
         <a href="#rid77">
          77
         </a>
         ]. In most patients, these effects are transient and are easily managed by slowing the infusion rate and supportive care.
        </p>
        <p>
         Delayed (type IV) hypersensitivity reactions manifesting as a maculopapular rash are rare, although eosinophilia has been observed in 3 percent of patients receiving
         <a class="drug drug_general" data-topicid="9175" href="/z/d/drug information/9175.html" rel="external">
          caspofungin
         </a>
         [
         <a href="#rid85">
          85
         </a>
         ]. Anaphylaxis has been reported rarely with each of the echinocandins. Post-marketing reports for caspofungin include rare cases consistent with a hypersensitivity syndrome, erythema multiforme, Stevens-Johnson syndrome, and skin exfoliation, although it is not clear that these reactions were caused by caspofungin [
         <a href="#rid76">
          76
         </a>
         ].
        </p>
        <p>
         Fever appears to be more common with
         <a class="drug drug_general" data-topicid="9175" href="/z/d/drug information/9175.html" rel="external">
          caspofungin
         </a>
         than other echinocandins, with rates ranging from 4 to 26 percent in clinical trials compared with &lt;1 percent for
         <a class="drug drug_general" data-topicid="8744" href="/z/d/drug information/8744.html" rel="external">
          anidulafungin
         </a>
         and
         <a class="drug drug_general" data-topicid="10141" href="/z/d/drug information/10141.html" rel="external">
          micafungin
         </a>
         [
         <a href="#rid86">
          86
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1239298227">
         <span class="h2">
          Injection site pain
         </span>
         <span class="headingEndMark">
          —
         </span>
         Injection site pain and phlebitis have been reported more frequently with
         <a class="drug drug_general" data-topicid="9175" href="/z/d/drug information/9175.html" rel="external">
          caspofungin
         </a>
         (4 to 25 percent) than
         <a class="drug drug_general" data-topicid="10141" href="/z/d/drug information/10141.html" rel="external">
          micafungin
         </a>
         (1 to 14 percent) or
         <a class="drug drug_general" data-topicid="8744" href="/z/d/drug information/8744.html" rel="external">
          anidulafungin
         </a>
         (&lt;1 percent), particularly when caspofungin is administered through a peripheral catheter. If these adverse effects occur, the infusion can be slowed down or the echinocandin can be administered in a more dilute solution.
        </p>
        <p>
         <strong>
          Gastrointestinal
         </strong>
         — Nausea, vomiting, diarrhea, and abdominal pain have been reported in approximately 1 to 3 percent of patients receiving echinocandin therapy but rarely result in drug discontinuation [
         <a href="#rid64">
          64,76,77
         </a>
         ]. For
         <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">
          ibrexafungerp
         </a>
         , the most common adverse effects include nausea, vomiting, abdominal pain, and diarrhea.
        </p>
        <p class="headingAnchor" id="H1239298234">
         <span class="h2">
          Renal toxicity
         </span>
         <span class="headingEndMark">
          —
         </span>
         No significant drug-related nephrotoxicity was observed with any of the echinocandins or with
         <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">
          ibrexafungerp
         </a>
         in clinical trials or documented in postmarketing surveillance [
         <a href="#rid64">
          64,76,77
         </a>
         ]. Modest rates of hypokalemia have been observed with all four echinocandins (2 to 11 percent), which may represent renal wasting.
        </p>
        <p class="headingAnchor" id="H1239298248">
         <span class="h2">
          Hematologic effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         Anemia, leukopenia, neutropenia, and thrombocytopenia have been reported and are limited to rare case reports (&lt;1 percent) [
         <a href="#rid64">
          64,76,77
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3324455553">
         <span class="h2">
          Cardiac toxicity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Echinocandins have been associated with low rates of cardiac adverse effects, especially relative to amphotericin B and triazoles. Some acute cardiovascular events in patients may be associated with histamine release during intravenous infusion. A review of preclinical and animal studies suggested that
         <a class="drug drug_general" data-topicid="9175" href="/z/d/drug information/9175.html" rel="external">
          caspofungin
         </a>
         and
         <a class="drug drug_general" data-topicid="8744" href="/z/d/drug information/8744.html" rel="external">
          anidulafungin
         </a>
         may have a greater potential for direct mitochondrial injury in cardiac myocytes compared with
         <a class="drug drug_general" data-topicid="10141" href="/z/d/drug information/10141.html" rel="external">
          micafungin
         </a>
         [
         <a href="#rid87">
          87
         </a>
         ]. However, the clinical significance of these observations is unknown, and documented cases of heart failure with caspofungin, anidulafungin, or micafungin are extremely rare (one to four cases per year for each echinocandin).
        </p>
        <p class="headingAnchor" id="H1239298262">
         <span class="h1">
          PREGNANCY
         </span>
        </p>
        <p class="headingAnchor" id="H1239298269">
         <span class="h2">
          Fetal development
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are no adequate studies of the echinocandins in pregnant women [
         <a href="#rid64">
          64,76,77
         </a>
         ]. Embryo-fetal development studies in rats and mice performed with doses twofold higher than human exposures resulted in skeletal changes in rat fetuses and increased abortion and visceral abnormalities in rabbits. Echinocandins appear to cross the placental barrier in rats and could be detected in the plasma of the fetus.
        </p>
        <p>
         All four echinocandins are classified as pregnancy category class C agents; they should therefore only be used if the potential benefit justifies the risk to the fetus.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">
          Ibrexafungerp
         </a>
         causes fetal harm and is contraindicated in pregnancy. Before beginning treatment, it is important to verify pregnancy status in persons of reproductive potential, and reassessment of pregnancy status prior to each dose is recommended if ibrexafungerp is used monthly for recurrent vulvovaginal candidiasis (VVC). For treatment of VVC, effective contraception should be used during treatment and for at least four days after the last dose or continued for an entire treatment period for recurrent VVC.
        </p>
        <p class="headingAnchor" id="H1239298276">
         <span class="h2">
          Breast milk
         </span>
         <span class="headingEndMark">
          —
         </span>
         It is unknown whether
         <a class="drug drug_general" data-topicid="9175" href="/z/d/drug information/9175.html" rel="external">
          caspofungin
         </a>
         ,
         <a class="drug drug_general" data-topicid="10141" href="/z/d/drug information/10141.html" rel="external">
          micafungin
         </a>
         ,
         <a class="drug drug_general" data-topicid="8744" href="/z/d/drug information/8744.html" rel="external">
          anidulafungin
         </a>
         , or
         <a class="drug drug_general" data-topicid="141155" href="/z/d/drug information/141155.html" rel="external">
          rezafungin
         </a>
         are excreted in human breast milk. Because all four echinocandins are 90 percent bound to plasma proteins and have poor oral bioavailability, they are unlikely to reach the milk and be absorbed by the infant. Therefore, if echinocandin therapy is required by the mother, there is no specific indication to discontinue breastfeeding [
         <a href="#rid88">
          88
         </a>
         ]. No information is available on the use of
         <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">
          ibrexafungerp
         </a>
         during breastfeeding. The drug is over 99 percent protein bound, so excretion in breast milk is likely to be very low. If ibrexafungerp is required by the mother of an older infant, there is no specific recommendation to discontinue breastfeeding, but until more data become available, an alternate drug may be preferred, especially while nursing a newborn or preterm infant [
         <a href="#rid88">
          88
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1239298283">
         <span class="h2">
          Mutagenesis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Echinocandins do not show evidence of mutagenic or genotoxic potential when evaluated by the standard battery of in vitro and in vivo tests [
         <a href="#rid64">
          64,76,77
         </a>
         ]. Fertility in rats is not affected by intravenous administration of any of the echinocandins. Long-term studies in animals to evaluate the carcinogenic potential of these echinocandins have not been performed.
        </p>
        <p class="headingAnchor" id="H1239300816">
         <span class="h1">
          DRUG INTERACTIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Echinocandins are not significant inhibitors or inducers of cytochrome P450 metabolism or p-glycoprotein drug efflux transporters. As a result, echinocandins generally have a lower risk for pharmacokinetic drug-drug interactions compared with other systemic antifungals. Of the comparatively few significant drug interactions involving echinocandins that have been identified to date, most involve the effect of
         <a class="drug drug_general" data-topicid="9175" href="/z/d/drug information/9175.html" rel="external">
          caspofungin
         </a>
         or
         <a class="drug drug_general" data-topicid="10141" href="/z/d/drug information/10141.html" rel="external">
          micafungin
         </a>
         upon immunosuppressive agents or the effect of other drugs upon caspofungin via enzyme induction.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">
          Ibrexafungerp
         </a>
         is unique in that it is both a substrate and inhibitor of CYP3A4 and P-glycoprotein. Therefore, ibrexafungerp has a greater potential for drug-drug interactions compared to other echinocandins.
        </p>
        <p>
         Echinocandin drug interactions will be briefly reviewed here. In addition, details about specific interactions may be obtained by using the
         <a class="external" href="/drug-interactions">
          drug interactions program
         </a>
         included within UpToDate.
        </p>
        <p class="headingAnchor" id="H1239301213">
         <span class="h2">
          Caspofungin
         </span>
         <span class="headingEndMark">
          —
         </span>
         The mechanism(s) by which
         <a class="drug drug_general" data-topicid="9175" href="/z/d/drug information/9175.html" rel="external">
          caspofungin
         </a>
         interacts with other drugs have not been firmly established. It has been suggested that organic anion transporting polypeptides, such as OATP-1B1, which mediate uptake of some drugs to hepatocytes, may play a role in drug interactions of caspofungin [
         <a href="#rid62">
          62,89
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          Cyclosporine
         </a>
         is an inhibitor of OATP-1B1 transporters and, when administered concurrently with
         <a class="drug drug_general" data-topicid="9175" href="/z/d/drug information/9175.html" rel="external">
          caspofungin
         </a>
         , has been shown to increase the total plasma concentration exposure of caspofungin (also known as area under curve [AUC]) by approximately 35 percent [
         <a href="#rid76">
          76
         </a>
         ]. On the other hand, caspofungin caused no significant alteration of cyclosporine time versus plasma concentration profile [
         <a href="#rid76">
          76
         </a>
         ]. The US Food and Drug Administration (FDA)-approved product information recommends caution when caspofungin and cyclosporine are given concurrently due to potentially increased risk of hepatotoxicity as evidenced by transient elevations in hepatic aminotransferases. Should the benefits of concurrent therapy outweigh the risks, monitoring of liver function tests is warranted [
         <a href="#rid67">
          67,76
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9175" href="/z/d/drug information/9175.html" rel="external">
          Caspofungin
         </a>
         decreases
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         serum concentrations by approximately 20 percent; however, no additional interventions are recommended beyond routine monitoring of tacrolimus blood levels, and dosage adjustment is necessary to avoid effects of subtherapeutic levels, including acute graft rejection [
         <a href="#rid67">
          67,76,90
         </a>
         ].
        </p>
        <p>
         Coadministration of
         <a class="drug drug_general" data-topicid="9175" href="/z/d/drug information/9175.html" rel="external">
          caspofungin
         </a>
         with
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         has been shown to induce caspofungin metabolism via an unknown mechanism [
         <a href="#rid91">
          91
         </a>
         ]; rifampin-mediated induction of OATP-1B1 may contribute. Therefore, an increased maintenance dose of 70 mg per day of caspofungin is recommended in patients who are receiving concomitant rifampin [
         <a href="#rid92">
          92
         </a>
         ]. A similar dose increase is recommended in patients receiving other enzyme inducers, such as
         <a class="drug drug_general" data-topicid="8731" href="/z/d/drug information/8731.html" rel="external">
          efavirenz
         </a>
         ,
         <a class="drug drug_general" data-topicid="9694" href="/z/d/drug information/9694.html" rel="external">
          nevirapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9769" href="/z/d/drug information/9769.html" rel="external">
          phenytoin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">
          dexamethasone
         </a>
         , and
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         [
         <a href="#rid76">
          76
         </a>
         ]. (See
         <a class="local">
          'Enzyme induction'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H1239300837">
         <span class="h2">
          Micafungin
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="10141" href="/z/d/drug information/10141.html" rel="external">
          Micafungin
         </a>
         modestly reduces the clearance of
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         ,
         <a class="drug drug_general" data-topicid="10329" href="/z/d/drug information/10329.html" rel="external">
          sirolimus
         </a>
         (rapamycin), and
         <a class="drug drug_general" data-topicid="9700" href="/z/d/drug information/9700.html" rel="external">
          nifedipine
         </a>
         [
         <a href="#rid64">
          64
         </a>
         ]. Routine dose adjustments of these agents are not necessary, but cyclosporine and sirolimus serum concentrations should be monitored. For patients receiving micafungin and nifedipine, blood pressure should be monitored and the dose of nifedipine can be reduced if necessary [
         <a href="#rid64">
          64
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1239301205">
         <span class="h2">
          Anidulafungin
         </span>
         <span class="headingEndMark">
          —
         </span>
         Among the echinocandins,
         <a class="drug drug_general" data-topicid="8744" href="/z/d/drug information/8744.html" rel="external">
          anidulafungin
         </a>
         is the least likely to be an object, or cause, of a pharmacokinetic drug interaction because it is not a substrate, inhibitor, or inducer of cytochrome P450 or P-glycoprotein. Anidulafungin does not alter the metabolism or clearance of
         <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">
          cyclosporine
         </a>
         . A modest increase (22 percent) in the total drug plasma concentration exposure (AUC) of anidulafungin was observed when coadministered with cyclosporine [
         <a href="#rid93">
          93
         </a>
         ]. The modest degree of this effect does not require dose adjustment or other specific management.
        </p>
        <p>
         Concurrent administration of
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         ,
         <a class="drug drug_general" data-topicid="9499" href="/z/d/drug information/9499.html" rel="external">
          liposomal amphotericin B
         </a>
         , or a variety of other substrates, inducers, or inhibitors of cytochrome P450 does not have a significant impact on the plasma drug concentration profile of
         <a class="drug drug_general" data-topicid="8744" href="/z/d/drug information/8744.html" rel="external">
          anidulafungin
         </a>
         [
         <a href="#rid80">
          80
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H943659242">
         <span class="h2">
          Rezafungin
         </span>
         <span class="headingEndMark">
          —
         </span>
         In both in vitro and in vivo studies,
         <a class="drug drug_general" data-topicid="141155" href="/z/d/drug information/141155.html" rel="external">
          rezafungin
         </a>
         demonstrates a low drug interaction potential via CYP substrate/transporter pathways and commonly prescribed comedications, suggesting that coadministration is unlikely to result in clinically significant drug interactions [
         <a href="#rid94">
          94
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1621189739">
         <span class="h3">
          Ibrexafungerp
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">
          Ibrexafungerp
         </a>
         coadministration (750 or 1500 mg/day) resulted in a 1.42-, 1.40-, and 2.82- fold increase in the AUC of
         <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">
          tacrolimus
         </a>
         (sensitive CYP3A substrate and P-glycoprotein substrate),
         <a class="drug drug_general" data-topicid="8926" href="/z/d/drug information/8926.html" rel="external">
          dabigatran
         </a>
         (P-glycoprotein substrate), and
         <a class="drug drug_general" data-topicid="9804" href="/z/d/drug information/9804.html" rel="external">
          pravastatin
         </a>
         (OATP1B substrate), respectively. However, because of the high doses used in the studies and the expected short duration of ibrexafungerp therapy, these results did not result in recommended dosing changes [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1239300844">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Available echinocandins
         </strong>
         – Four semisynthetic echinocandin derivatives have been developed for clinical use:
         <a class="drug drug_general" data-topicid="9175" href="/z/d/drug information/9175.html" rel="external">
          caspofungin
         </a>
         ,
         <a class="drug drug_general" data-topicid="10141" href="/z/d/drug information/10141.html" rel="external">
          micafungin
         </a>
         ,
         <a class="drug drug_general" data-topicid="8744" href="/z/d/drug information/8744.html" rel="external">
          anidulafungin
         </a>
         , and
         <a class="drug drug_general" data-topicid="141155" href="/z/d/drug information/141155.html" rel="external">
          rezafungin
         </a>
         . (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">
          Ibrexafungerp
         </a>
         is a triterpenoid antifungal with a similar mechanism of action as echinocandins that is available orally. However, it is only approved for the treatment of vulvovaginal and recurrent vulvovaginal candidiasis (VVC).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mechanism and spectrum of activity
         </strong>
         – Echinocandins are believed to elicit their antifungal activity by binding to the Fks protein subunit of the enzyme, thereby blocking the beta-(1,3)-D-glucan synthesis  (
         <a class="graphic graphic_figure graphicRef67408" href="/z/d/graphic/67408.html" rel="external">
          figure 2
         </a>
         ). These agents are fungicidal for susceptible
         <em>
          Candida
         </em>
         and fungistatic for
         <em>
          Aspergillus
         </em>
         spp. (See
         <a class="local">
          'Mechanism of action'
         </a>
         above and
         <a class="local">
          'Microbiologic activity'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Clinical uses
         </strong>
         – Echinocandins are widely used for the treatment of invasive candidiasis, especially in critically-ill and neutropenic patients, and less commonly in salvage regimens for invasive aspergillosis. They are also used for empiric antifungal therapy in patients with febrile neutropenia. Experience with this antifungal class suggests that it is the best tolerated and safest class available.(See
         <a class="local">
          'Overview of clinical uses'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Selecting an echinocandin
         </strong>
         – Because all four echinocandins share a similar spectrum of activity and mechanism of action, most experts consider these drugs to be interchangeable, particularly for the treatment of invasive candidiasis  (
         <a class="graphic graphic_table graphicRef107624" href="/z/d/graphic/107624.html" rel="external">
          table 1
         </a>
         ). However, the four echinocandins differ in terms of their dosing, pathways of metabolic elimination, and drug interaction profile. Therefore, it is important to appreciate these unique characteristics when selecting an echinocandin  (
         <a class="graphic graphic_table graphicRef56212" href="/z/d/graphic/56212.html" rel="external">
          table 2
         </a>
         ) (see
         <a class="local">
          'Overview of clinical uses'
         </a>
         above and
         <a class="local">
          'Pharmacokinetics'
         </a>
         above).
         <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">
          Ibrexafungerp
         </a>
         has a similar spectrum to the echinocandins but uniquely different pharmacokinetics and is only approved for the treatment of VVC and recurrent VVC.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Advantages
         </strong>
         – The major advantages of echinocandins relative to other antifungal agents are their fungicidal activity against
         <em>
          Candida
         </em>
         spp, including fluconazole-resistant
         <em>
          C. glabrata
         </em>
         and
         <em>
          C. krusei
         </em>
         , combined with their relatively low potential for renal or hepatic toxicity or serious drug-drug interactions (see
         <a class="local">
          'Overview of clinical uses'
         </a>
         above). Echinocandins are the drugs of choice for
         <em>
          C. auris
         </em>
         but resistance is increasing, emphasizing the importance of susceptibility testing.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Adverse effects
         </strong>
         – Echinocandins are well tolerated, and all four members of the class have similar types of adverse effects. Serious adverse effects requiring drug discontinuation occur less frequently with the echinocandins than with other classes of systemic antifungals (see
         <a class="local">
          'Adverse effects'
         </a>
         above).
         <a class="drug drug_general" data-topicid="131762" href="/z/d/drug information/131762.html" rel="external">
          Ibrexafungerp
         </a>
         is also well tolerated but may be associated with gastrointestinal side effects and is contraindicated in pregnancy because of risk of fetal harm.
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Hector RF. Compounds active against cell walls of medically important fungi. Clin Microbiol Rev 1993; 6:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Debono M, Gordee RS. Antibiotics that inhibit fungal cell wall development. Annu Rev Microbiol 1994; 48:471.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Denning DW. Echinocandin antifungal drugs. Lancet 2003; 362:1142.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pappas PG, Kauffman CA, Andes DR, et al. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis 2016; 62:e1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sobel R, Nyirjesy P, Ghannoum MA, et al. Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: a global phase 3, randomised, placebo-controlled superiority study (VANISH 306). BJOG 2022; 129:412.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lyman M, Forsberg K, Sexton DJ, et al. Worsening Spread of Candida auris in the United States, 2019 to 2021. Ann Intern Med 2023; 176:489.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Douglas CM. Fungal beta(1,3)-D-glucan synthesis. Med Mycol 2001; 39 Suppl 1:55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cabib E, Roh DH, Schmidt M, et al. The yeast cell wall and septum as paradigms of cell growth and morphogenesis. J Biol Chem 2001; 276:19679.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fleet GH. Composition and structure of yeast cell walls. Curr Top Med Mycol 1985; 1:24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bernard M, Latgé JP. Aspergillus fumigatus cell wall: composition and biosynthesis. Med Mycol 2001; 39 Suppl 1:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beauvais A, Bruneau JM, Mol PC, et al. Glucan synthase complex of Aspergillus fumigatus. J Bacteriol 2001; 183:2273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beauvais A, Latgé JP. Membrane and cell wall targets in Aspergillus fumigatus. Drug Resist Updat 2001; 4:38.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kurtz MB, Heath IB, Marrinan J, et al. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase. Antimicrob Agents Chemother 1994; 38:1480.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wheeler RT, Fink GR. A drug-sensitive genetic network masks fungi from the immune system. PLoS Pathog 2006; 2:e35.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wheeler RT, Kombe D, Agarwala SD, Fink GR. Dynamic, morphotype-specific Candida albicans beta-glucan exposure during infection and drug treatment. PLoS Pathog 2008; 4:e1000227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hohl TM, Feldmesser M, Perlin DS, Pamer EG. Caspofungin modulates inflammatory responses to Aspergillus fumigatus through stage-specific effects on fungal beta-glucan exposure. J Infect Dis 2008; 198:176.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ibrahim AS, Bowman JC, Avanessian V, et al. Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. Antimicrob Agents Chemother 2005; 49:721.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lamaris GA, Lewis RE, Chamilos G, et al. Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae. J Infect Dis 2008; 198:186.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfaller MA, Boyken L, Hollis RJ, et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 2008; 46:150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfaller MA, Castanheira M, Lockhart SR, et al. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J Clin Microbiol 2012; 50:1199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfaller MA. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am J Med 2012; 125:S3.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zimbeck AJ, Iqbal N, Ahlquist AM, et al. FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance. Antimicrob Agents Chemother 2010; 54:5042.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfaller MA, Diekema DJ, Turnidge JD, et al. Twenty Years of the SENTRY Antifungal Surveillance Program: Results for Candida Species From 1997-2016. Open Forum Infect Dis 2019; 6:S79.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chapeland-Leclerc F, Hennequin C, Papon N, et al. Acquisition of flucytosine, azole, and caspofungin resistance in Candida glabrata bloodstream isolates serially obtained from a hematopoietic stem cell transplant recipient. Antimicrob Agents Chemother 2010; 54:1360.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dannaoui E, Desnos-Ollivier M, Garcia-Hermoso D, et al. Candida spp. with acquired echinocandin resistance, France, 2004-2010. Emerg Infect Dis 2012; 18:86.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dodgson KJ, Dodgson AR, Pujol C, et al. Caspofungin resistant C. glabrata. Clin Microbiol Infect 2005; 11 (Suppl 2):364.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kofteridis DP, Lewis RE, Kontoyiannis DP. Caspofungin-non-susceptible Candida isolates in cancer patients. J Antimicrob Chemother 2010; 65:293.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Krogh-Madsen M, Arendrup MC, Heslet L, Knudsen JD. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clin Infect Dis 2006; 42:938.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfaller MA, Castanheira M, Lockhart SR, et al. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J Clin Microbiol 2012; 50:1199.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pham CD, Iqbal N, Bolden CB, et al. Role of FKS Mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance. Antimicrob Agents Chemother 2014; 58:4690.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfaller MA, Carvalhaes C, Messer SA, et al. Activity of a Long-Acting Echinocandin, Rezafungin, and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates (SENTRY Program, 2016 to 2018). Antimicrob Agents Chemother 2020; 64.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alexander BD, Johnson MD, Pfeiffer CD, et al. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clin Infect Dis 2013; 56:1724.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Beyda ND, John J, Kilic A, et al. FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia. Clin Infect Dis 2014; 59:819.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang E, Farmakiotis D, Yang D, et al. The ever-evolving landscape of candidaemia in patients with acute leukaemia: non-susceptibility to caspofungin and multidrug resistance are associated with increased mortality. J Antimicrob Chemother 2015; 70:2362.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bader JC, Lakota EA, Flanagan S, et al. Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata. Antimicrob Agents Chemother 2018; 62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nunnally NS, Etienne KA, Angulo D, et al. In Vitro Activity of Ibrexafungerp, a Novel Glucan Synthase Inhibitor against Candida glabrata Isolates with FKS Mutations. Antimicrob Agents Chemother 2019; 63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berkow EL, Angulo D, Lockhart SR. In Vitro Activity of a Novel Glucan Synthase Inhibitor, SCY-078, against Clinical Isolates of Candida auris. Antimicrob Agents Chemother 2017; 61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramage G, VandeWalle K, Bachmann SP, et al. In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies. Antimicrob Agents Chemother 2002; 46:3634.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuhn DM, George T, Chandra J, et al. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother 2002; 46:1773.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nett J, Lincoln L, Marchillo K, Andes D. Beta -1,3 glucan as a test for central venous catheter biofilm infection. J Infect Dis 2007; 195:1705.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cassone A, Kerridge D, Gale EF. Ultrastructural changes in the cell wall of Candida albicans following cessation of growth and their possible relationship to the development of polyene resistance. J Gen Microbiol 1979; 110:339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gale EF, Ingram J, Kerridge D, et al. Reduction of amphotericin resistance in stationary phase cultures of Candida albicans by treatment with enzymes. J Gen Microbiol 1980; 117:383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nett J, Lincoln L, Marchillo K, et al. Putative role of beta-1,3 glucans in Candida albicans biofilm resistance. Antimicrob Agents Chemother 2007; 51:510.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Arendrup MC, Boekhout T, Akova M, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections. Clin Microbiol Infect 2014; 20 Suppl 3:76.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stanzani M, Cricca M, Sassi C, et al. Saprochaete clavata infections in patients undergoing treatment for haematological malignancies: A report of a monocentric outbreak and review of the literature. Mycoses 2019; 62:1100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bowman JC, Hicks PS, Kurtz MB, et al. The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob Agents Chemother 2002; 46:3001.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ben-Ami R, Lewis RE, Kontoyiannis DP. Immunocompromised hosts: immunopharmacology of modern antifungals. Clin Infect Dis 2008; 47:226.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Espinel-Ingroff A. Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 1998; 36:2950.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tawara S, Ikeda F, Maki K, et al. In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother 2000; 44:57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kahn JN, Hsu MJ, Racine F, et al. Caspofungin susceptibility in Aspergillus and non-Aspergillus molds: inhibition of glucan synthase and reduction of beta-D-1,3 glucan levels in culture. Antimicrob Agents Chemother 2006; 50:2214.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Del Poeta M, Schell WA, Perfect JR. In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds. Antimicrob Agents Chemother 1997; 41:1835.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ito M, Nozu R, Kuramochi T, et al. Prophylactic effect of FK463, a novel antifungal lipopeptide, against Pneumocystis carinii infection in mice. Antimicrob Agents Chemother 2000; 44:2259.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schmatz DM, Powles M, McFadden DC, et al. Treatment and prevention of Pneumocystis carinii pneumonia and further elucidation of the P. carinii life cycle with 1,3-beta-glucan synthesis inhibitor L-671,329. J Protozool 1991; 38:151S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kottom TJ, Limper AH. Cell wall assembly by Pneumocystis carinii. Evidence for a unique gsc-1 subunit mediating beta -1,3-glucan deposition. J Biol Chem 2000; 275:40628.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kohler S, Wheat LJ, Connolly P, et al. Comparison of the echinocandin caspofungin with amphotericin B for treatment of histoplasmosis following pulmonary challenge in a murine model. Antimicrob Agents Chemother 2000; 44:1850.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dodds Ashley ES, Lewis R, Lewis JS, et al. Pharmacology of systemic antifungal agents. Clin Infect Dis 2006; 43 Suppl 1:S28.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCarthy MW. Pharmacokinetics and Pharmacodynamics of Ibrexafungerp. Drugs R D 2022; 22:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yu J, Wang Y, Ragueneau-Majlessi I. Strong Pharmacokinetic Drug-Drug Interactions With Drugs Approved by the US Food and Drug Administration in 2021: Mechanisms and Clinical Implications. Clin Ther 2022; 44:1536.
          </a>
         </li>
         <li class="breakAll">
          CANCIDAS (caspofungin acetate) for injection, for intravenous use, prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021227s038lbl.pdf (Accessed on March 27, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stone JA, Holland SD, Wickersham PJ, et al. Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob Agents Chemother 2002; 46:739.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sucher AJ, Chahine EB, Balcer HE. Echinocandins: the newest class of antifungals. Ann Pharmacother 2009; 43:1647.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stone JA, Xu X, Winchell GA, et al. Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma. Antimicrob Agents Chemother 2004; 48:815.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boucher HW, Groll AH, Chiou CC, Walsh TJ. Newer systemic antifungal agents : pharmacokinetics, safety and efficacy. Drugs 2004; 64:1997.
          </a>
         </li>
         <li class="breakAll">
          Mycamine (micafungin sodium) for injection, IV infusion only, prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021506s019lbl.pdf (Accessed on March 27, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ong V, Wills S, Watson D, et al. Metabolism, Excretion, and Mass Balance of [14C]-Rezafungin in Animals and Humans. Antimicrob Agents Chemother 2022; 66:e0139021.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Theuretzbacher U. Pharmacokinetics/pharmacodynamics of echinocandins. Eur J Clin Microbiol Infect Dis 2004; 23:805.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cappelletty D, Eiselstein-McKitrick K. The echinocandins. Pharmacotherapy 2007; 27:369.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lehrnbecher T, Groll AH. Micafungin: a brief review of pharmacology, safety, and antifungal efficacy in pediatric patients. Pediatr Blood Cancer 2010; 55:229.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Walsh TJ, Adamson PC, Seibel NL, et al. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother 2005; 49:4536.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Neely M, Jafri HS, Seibel N, et al. Pharmacokinetics and safety of caspofungin in older infants and toddlers. Antimicrob Agents Chemother 2009; 53:1450.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sáez-Llorens X, Macias M, Maiya P, et al. Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age. Antimicrob Agents Chemother 2009; 53:869.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seibel NL, Schwartz C, Arrieta A, et al. Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother 2005; 49:3317.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heresi GP, Gerstmann DR, Blumer JL, et al. Pharmacokinetic, safety, and tolerance study of micafungin (FK463) in premature infants. Pediat Res 2003; 53:317A.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hope WW, Mickiene D, Petraitis V, et al. The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. J Infect Dis 2008; 197:163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hope WW, Smith PB, Arrieta A, et al. Population pharmacokinetics of micafungin in neonates and young infants. Antimicrob Agents Chemother 2010; 54:2633.
          </a>
         </li>
         <li class="breakAll">
          Cancidas (caspofungin acetate) for injection, for intravenous use, prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021227s038lbl.pdf (Accessed on March 27, 2023).
         </li>
         <li class="breakAll">
          Eraxis (anidulafungin) for injection, prescribing information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021632s000,021948s000lbl.pdf (Accessed on March 27, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weiler S, Seger C, Pfisterer H, et al. Pharmacokinetics of caspofungin in critically ill patients on continuous renal replacement therapy. Antimicrob Agents Chemother 2013; 57:4053.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gustot T, Ter Heine R, Brauns E, et al. Caspofungin dosage adjustments are not required for patients with Child-Pugh B or C cirrhosis. J Antimicrob Chemother 2018; 73:2493.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dowell JA, Knebel W, Ludden T, et al. Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J Clin Pharmacol 2004; 44:590.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nguyen TH, Hoppe-Tichy T, Geiss HK, et al. Factors influencing caspofungin plasma concentrations in patients of a surgical intensive care unit. J Antimicrob Chemother 2007; 60:100.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hall RG, Swancutt MA, Gumbo T. Fractal geometry and the pharmacometrics of micafungin in overweight, obese, and extremely obese people. Antimicrob Agents Chemother 2011; 55:5107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jullien V, Azoulay E, Schwebel C, et al. Population pharmacokinetics of micafungin in ICU patients with sepsis and mechanical ventilation. J Antimicrob Chemother 2017; 72:181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spriet I, Annaert P, Meersseman P, et al. Pharmacokinetics of caspofungin and voriconazole in critically ill patients during extracorporeal membrane oxygenation. J Antimicrob Chemother 2009; 63:767.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deresinski SC, Stevens DA. Caspofungin. Clin Infect Dis 2003; 36:1445.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eschenauer G, Depestel DD, Carver PL. Comparison of echinocandin antifungals. Ther Clin Risk Manag 2007; 3:71.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cleary JD, Stover KR. Antifungal-Associated Drug-Induced Cardiac Disease. Clin Infect Dis 2015; 61 Suppl 6:S662.
          </a>
         </li>
         <li class="breakAll">
          Drugs and Lactation Database (LactMed®). National Library of Medicine. Available at: https://www.ncbi.nlm.nih.gov/books/NBK501922/ (Accessed on August 31, 2023).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sandhu P, Lee W, Xu X, et al. Hepatic uptake of the novel antifungal agent caspofungin. Drug Metab Dispos 2005; 33:676.
          </a>
         </li>
         <li class="breakAll">
          Cancidas [package insert]. Whitehouse Station, NJ: Merck&amp;Co. Inc; 2001.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meletiadis J, Chanock S, Walsh TJ. Human pharmacogenomic variations and their implications for antifungal efficacy. Clin Microbiol Rev 2006; 19:763.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stone JA, Migoya EM, Hickey L, et al. Potential for interactions between caspofungin and nelfinavir or rifampin. Antimicrob Agents Chemother 2004; 48:4306.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dowell JA, Stogniew M, Krause D, et al. Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine. J Clin Pharmacol 2005; 45:227.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flanagan S, Walker H, Ong V, Sandison T. Absence of Clinically Meaningful Drug-Drug Interactions with Rezafungin: Outcome of Investigations. Microbiol Spectr 2023; 11:e0133923.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 13945 Version 34.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8457977" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Compounds active against cell walls of medically important fungi.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7826015" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Antibiotics that inhibit fungal cell wall development.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14550704" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Echinocandin antifungal drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26679628" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34676663" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: a global phase 3, randomised, placebo-controlled superiority study (VANISH 306).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36940442" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Worsening Spread of Candida auris in the United States, 2019 to 2021.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11800269" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Fungal beta(1,3)-D-glucan synthesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11309404" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : The yeast cell wall and septum as paradigms of cell growth and morphogenesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3916769" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Composition and structure of yeast cell walls.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11800273" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Aspergillus fumigatus cell wall: composition and biosynthesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11244067" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Glucan synthase complex of Aspergillus fumigatus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11512152" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Membrane and cell wall targets in Aspergillus fumigatus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7979276" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16652171" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : A drug-sensitive genetic network masks fungi from the immune system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19057660" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Dynamic, morphotype-specific Candida albicans beta-glucan exposure during infection and drug treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18500928" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Caspofungin modulates inflammatory responses to Aspergillus fumigatus through stage-specific effects on fungal beta-glucan exposure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15673756" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18500936" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18032613" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22278842" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22196207" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20837754" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : FKS mutations and elevated echinocandin MIC values among Candida glabrata isolates from U.S. population-based surveillance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30895218" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Twenty Years of the SENTRY Antifungal Surveillance Program: Results for Candida Species From 1997-2016.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20038613" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Acquisition of flucytosine, azole, and caspofungin resistance in Candida glabrata bloodstream isolates serially obtained from a hematopoietic stem cell transplant recipient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22257484" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Candida spp. with acquired echinocandin resistance, France, 2004-2010.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Caspofungin resistant C. glabrata
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20016020" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Caspofungin-non-susceptible Candida isolates in cancer patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16511756" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22278842" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24890592" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Role of FKS Mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32015043" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Activity of a Long-Acting Echinocandin, Rezafungin, and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates (SENTRY Program, 2016 to 2018).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23487382" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24879785" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : FKS mutant Candida glabrata: risk factors and outcomes in patients with candidemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25855759" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : The ever-evolving landscape of candidaemia in patients with acute leukaemia: non-susceptibility to caspofungin and multidrug resistance are associated with increased mortality.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29555634" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31481447" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : In Vitro Activity of Ibrexafungerp, a Novel Glucan Synthase Inhibitor against Candida glabrata Isolates with FKS Mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28483955" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : In Vitro Activity of a Novel Glucan Synthase Inhibitor, SCY-078, against Clinical Isolates of Candida auris.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12384379" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12019089" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17471441" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Beta -1,3 glucan as a test for central venous catheter biofilm infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/374681" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Ultrastructural changes in the cell wall of Candida albicans following cessation of growth and their possible relationship to the development of polyene resistance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6999116" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Reduction of amphotericin resistance in stationary phase cultures of Candida albicans by treatment with enzymes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17130296" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Putative role of beta-1,3 glucans in Candida albicans biofilm resistance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24102785" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31365161" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Saprochaete clavata infections in patients undergoing treatment for haematological malignancies: A report of a monocentric outbreak and review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12183260" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18540822" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Immunocompromised hosts: immunopharmacology of modern antifungals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9738049" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10602723" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16723587" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Caspofungin susceptibility in Aspergillus and non-Aspergillus molds: inhibition of glucan synthase and reduction of beta-D-1,3 glucan levels in culture.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9257774" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10952565" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Prophylactic effect of FK463, a novel antifungal lipopeptide, against Pneumocystis carinii infection in mice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1818147" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Treatment and prevention of Pneumocystis carinii pneumonia and further elucidation of the P. carinii life cycle with 1,3-beta-glucan synthesis inhibitor L-671,329.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11013231" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Cell wall assembly by Pneumocystis carinii. Evidence for a unique gsc-1 subunit mediating beta -1,3-glucan deposition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10858342" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Comparison of the echinocandin caspofungin with amphotericin B for treatment of histoplasmosis following pulmonary challenge in a murine model.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Pharmacology of systemic antifungal agents
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34961907" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Pharmacokinetics and Pharmacodynamics of Ibrexafungerp.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36210218" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Strong Pharmacokinetic Drug-Drug Interactions With Drugs Approved by the US Food and Drug Administration in 2021: Mechanisms and Clinical Implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36210218" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Strong Pharmacokinetic Drug-Drug Interactions With Drugs Approved by the US Food and Drug Administration in 2021: Mechanisms and Clinical Implications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11850256" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Single- and multiple-dose pharmacokinetics of caspofungin in healthy men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19724014" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Echinocandins: the newest class of antifungals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14982770" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15341494" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Newer systemic antifungal agents : pharmacokinetics, safety and efficacy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15341494" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Newer systemic antifungal agents : pharmacokinetics, safety and efficacy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34662192" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Metabolism, Excretion, and Mass Balance of [14C]-Rezafungin in Animals and Humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15490294" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Pharmacokinetics/pharmacodynamics of echinocandins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17316149" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : The echinocandins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20583216" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Micafungin: a brief review of pharmacology, safety, and antifungal efficacy in pediatric patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16251293" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19114680" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Pharmacokinetics and safety of caspofungin in older infants and toddlers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19075070" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16048942" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Pharmacokinetic, safety, and tolerance study of micafungin (FK463) in premature infants
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18171300" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20308367" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Population pharmacokinetics of micafungin in neonates and young infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20308367" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Population pharmacokinetics of micafungin in neonates and young infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20308367" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Population pharmacokinetics of micafungin in neonates and young infants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23733471" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Pharmacokinetics of caspofungin in critically ill patients on continuous renal replacement therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29860319" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Caspofungin dosage adjustments are not required for patients with Child-Pugh B or C cirrhosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15145966" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17525052" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Factors influencing caspofungin plasma concentrations in patients of a surgical intensive care unit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21876061" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Fractal geometry and the pharmacometrics of micafungin in overweight, obese, and extremely obese people.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27609051" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Population pharmacokinetics of micafungin in ICU patients with sepsis and mechanical ventilation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19218271" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Pharmacokinetics of caspofungin and voriconazole in critically ill patients during extracorporeal membrane oxygenation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12766841" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Caspofungin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18360617" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Comparison of echinocandin antifungals.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26567285" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Antifungal-Associated Drug-Induced Cardiac Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26567285" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Antifungal-Associated Drug-Induced Cardiac Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15716364" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Hepatic uptake of the novel antifungal agent caspofungin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15716364" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Hepatic uptake of the novel antifungal agent caspofungin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17041143" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Human pharmacogenomic variations and their implications for antifungal efficacy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15504857" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Potential for interactions between caspofungin and nelfinavir or rifampin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15647416" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37154682" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Absence of Clinically Meaningful Drug-Drug Interactions with Rezafungin: Outcome of Investigations.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
